

29 April 2022

Tender results

Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2021/22 Invitation to Tender, dated 1 November 2021.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceuticals under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12th of May 2022 or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://www.Pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/Pharmaceutical-product-specifications-the-change-process>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/Pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode

2021/22 Tender – Principal Supply Status applies until 30 June 2025

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date
Docusate sodium with sennosides	Tab 50 mg with sennosides 8 mg; 200 tablet bottle	\$4.20	\$3.50	Laxsol (Aspen)	1 June 2022	1 November 2022
Losartan potassium with hydrochlorothiazide ¹	Tab 50 mg with hydrochlorothiazide 12.5 mg; 30 tablet blister pack	\$15.25	\$4.00	Arrow-Losartan & Hydrochlorothiazide (Teva)	1 August 2022	1 January 2023
¹ This product will be supplied at the Price from the 1 st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(ii) of the 2021/22 Invitation To Tender.						

2. *Tenders awarded to Pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date	Brand (Supplier) affected by delisting
Glycerol	Suppos 4 g; 20 suppository pack	\$9.25 (suppos 3.6 g)	\$10.39	Lax- Suppositories Glycerol (AFT)	1 September 2022	1 February 2023	PSM <i>suppos 3.6 mg</i> (API Consumer Brands)
Hydrocortisone	Crm 1%; 30 g OP tube	\$3.70 (per 100 g)	\$1.78	Ethics (Multichem)	1 November 2022	1 April 2023	Hydrocortisone (PSM) <i>100g pack size</i> (API Consumer Brands)
Levonorgestrel	Tab 1.5 mg; 1 tablet blister pack	\$4.95	\$1.75	Levonorgestrel BNM (Boucher)	1 January 2023	1 June 2023	Postinor-1 (Bayer)
Metoclopramide hydrochloride	Inj 5 mg per ml, 2 ml ampoule; 10 ampoule pack	\$9.50	\$7.00	Baxter (Baxter)	1 July 2022	1 December 2022	Pfizer (Pfizer)

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

3. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Date of listing	Principal Supply Status date
Docusate sodium with sennosides	Tab 50 mg with sennosides 8 mg; 200 tablet bottle	\$4.20	\$3.50	Laxsol (Aspen)	5%	1 June 2022	1 November 2022
Losartan potassium with hydrochlorothiazide ²	Tab 50 mg with hydrochlorothiazide 12.5 mg; 30 tablet blister pack	\$15.25	\$4.00	Arrow-Losartan & Hydrochlorothiazide (Teva)	5%	1 August 2022	1 January 2023
² This product will be supplied at the Price from the 1 st day of the month prior to the listing date, as per Schedule 6, clause 3.1 (b)(ii) of the 2021/22 Invitation To Tender.							

4. *Tenders awarded to Pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date	Brand (Supplier) affected by delisting
Glycerol	Suppos 4 g; 20 suppository pack	\$9.25 (suppos 3.6 g)	\$10.39	Lax-Suppositories Glycerol (AFT)	5% ³	1 September 2022	1 February 2023	PSM <i>suppos 3.6 mg</i> (API Consumer Brands) ⁴
Hydrocortisone	Crn 1%; 30 g tube	\$3.70 (per 100 g)	\$1.78	Ethics (Multichem)	5%	1 November 2022	1 April 2023	Hydrocortisone (PSM) <i>100g pack size</i> (API Consumer Brands)
Levonorgestrel	Tab 1.5 mg; 1 tablet blister pack	\$4.95	\$1.75	Levonorgestrel BNM (Boucher)	5%	1 January 2023	1 June 2023	Postinor-1 (Bayer)
Metoclopramide hydrochloride	Inj 5 mg per ml, 2 ml ampoule; 10 ampoule pack	\$9.50	\$7.00	Baxter (Baxter)	5%	1 July 2022	1 December 2022	Pfizer (Pfizer)
<p>³The following note will be added to the listing of "Glycerol suppos 4 g" as follows: "Note: DV limit applies to glycerol suppository presentations."</p> <p>⁴The following presentations will also be delisted from 1 February 2023: "Glycerol suppos 1.27 g" and "Glycerol suppos 2.55 g".</p>								

Tender declines - Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2021/22 Invitation to Tender, dated 1 November 2021.

Chemical name	Line item
Busulfan	Inj 6 mg per ml
Chlorhexidine with cetrimide	Irrigation soln 0.015% with cetrimide 0.15%, 500 ml
Chlorpromazine Hydrochloride	Inj 25 mg per ml, 2 ml ampoule
Chlorpromazine Hydrochloride	Tab 10 mg
Chlorpromazine Hydrochloride	Tab 25 mg
Chlorpromazine Hydrochloride	Tab 100 mg
Ethinylestradiol with Norethisterone	Tab 35 mcg with norethisterone 1 mg
Glyceryl trinitrate	Inj 5 mg per ml, 10 ml ampoule
Hydrocortisone	Oint 1% (pack size greater than 100 g)
Hydrocortisone	Oint 1% (pack size 100 g or less)

Chemical name	Line item
Lomustine	Cap 40 mg
Macrogol 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate	Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet
Macrogol 3350 with potassium chloride, sodium chloride, sodium sulfate and ascorbic acid [x1 sachet]; and citric acid with magnesium oxide and picosulfate [x2 sachets]	Powder for oral soln
Paracetamol	Suppos 25 mg
Paracetamol	Suppos 50 mg
Paracetamol with codeine	Tab paracetamol 500 mg with codeine phosphate 15 mg
Pholcodine	Oral liq 1 mg per ml
Prochlorperazine	Tab 3 mg buccal
Telmisartan	Tab 40 mg
Telmisartan	Tab 80 mg

Chemical name	Line item
Hydrocortisone with natamycin and neomycin	Crn 1% with natamycin 1% and
Lomustine	Cap 10 mg

Chemical name	Line item
Telmisartan with hydrochlorothiazide	Tab 40 mg with hydrochlorothiazide 12.5 mg
Telmisartan with hydrochlorothiazide	Tab 80 mg with hydrochlorothiazide 12.5 mg

For products included in the 2019/20, 2020/21 or 2021/22 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.